Successes and challenges in varicella vaccine.
Varicella is a highly contagious disease caused by primary infection with varicella zoster virus (VZV). VZV infection, as well as varicella vaccination, induces VZV-specific antibody and T-cell-mediated immunity, essential for recovery. The immune responses developed contribute to protection following re-exposure to VZV. When cell-mediated immunity declines, as occurs with aging or immunosuppression, reactivation of VZV leads to herpes zoster (HZ). It has been almost 20 years since universal varicella vaccination has been implemented in many areas around the globe and this has resulted in a significant reduction of varicella-associated disease burden. Successes are reviewed here, whilst emphasis is put on the challenges ahead. Most countries that have not implemented routine childhood varicella vaccination have chosen to vaccinate high-risk groups alone. The main reasons for not introducing universal vaccination are discussed, including fear of age shift of peak incidence age and of HZ incidence increase. Possible reasons for not observing the predicted increase in HZ incidence are explored. The advantages and disadvantages of universal vs targeted vaccination as well as different vaccination schedules are discussed.
Second Department of Pediatrics, University of Athens Medical School, P&A Kyriakou Childrens' Hospital, Greece.
Orestis
O
Papaloukas
Second Department of Pediatrics, University of Athens Medical School, P&A Kyriakou Childrens' Hospital, Greece.
Georgia
G
Giannouli
Third Department of Pediatrics, University of Athens Medical School, General University Hospital 'ATTIKON', Rimini 1, Chaidari 124 62, Greece.
Vassiliki
V
Papaevangelou
VZV-cellular immunity; Varicella vaccination; epidemiology; herpes zoster incidence; varicella zoster virus